Eurofins Scientific (EURONEXT:ERF) posted H1 2026 revenue of €3.7bn (organic +2.7%) with €302m net profit and strong FCF, while agreeing to buy Element Materials’ North America Life Sciences unit for $400m to expand lab capacity and add >$150m revenue potential.
Previous Week Recap
- Eurofins 2026 H1 Revenue, EBITDA, Profit: Eurofins (ERF) H1 2026: revenues €3.7bn (+2.5%), organic +2.7%, adjusted EBITDA €877m (23.7%), net profit €302m, EPS €1.55, FCF €469m, net debt €3.85bn, 17 acquisitions ~€138m.
- Eurofins To Buy Element North America Unit: Eurofins Scientific (ERF) to buy Element Materials’ North America Life Sciences unit for $400M; deal closes Q4 2026 pending approvals. Unit: 27 labs, ~750 staff, >$150M projected 2026 revenue.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.